Inhibitors of HGFA, matriptase, and hepsin serine proteases: A nonkinase strategy to block cell signaling in cancer

ACS Medicinal Chemistry Letters

Volumn 5, Issue 11, 2014, Pages 1219-1224

  Han, Zhenfu ^a   Harris, Peter K W ^a   Jones, Darin E ^a,c   Chugani, Ryan ^a   Kim, Tommy ^a   Agarwal, Manjula ^a   Shen, Wei ^b   Wildman, Scott A ^a   Janetka, James W ^a  

^a Washington University in St Louis School of Medicine   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Department of Chemistry University of Arkansas ^*  (United States)

Author keywords

breast cancer; c MET; cell signaling; growth factor; hepsin; HGF; HGFA; inhibitor; ketothiazole; kinase; matriptase; MSP; peptidomimetic; RON; serine protease; solid phase peptide synthesis

Indexed keywords

ANTINEOPLASTIC AGENT; ENZYME PRECURSOR; HEPATOCYTE GROWTH FACTOR ACTIVATOR; HEPSIN; MACROPHAGE STIMULATING PROTEIN; MATRIPTASE; PEPTIDOMIMETIC AGENT; PROTEIN; PROTEIN TYROSINE KINASE; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER INHIBITION; DOSE RESPONSE; DRUG DEVELOPMENT; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; EC50; ENZYME INHIBITION; ENZYME KINETIC ASSAY; MAP KINASE ASSAY; NEOPLASM; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN CONFORMATION; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION; SOLID PHASE PEPTIDE SYNTHESIS; SOLID PHASE SYNTHESIS; STRUCTURE ACTIVITY RELATION;

EID: 84927624123     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml500254r     Document Type: Article

References (42)

1. Gaudino, G.; Follenzi, A.; Naldini, L.; Collesi, C.; Santoro, M.; Gallo, K. A.; Godowski, P. J.; Comoglio, P. M. RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP EMBO J. 1994, 13 (15) 3524-32
2. Organ, S. L.; Tsao, M. S. An overview of the c-MET signaling pathway Ther. Adv. Med. Oncol. 2011, 3 (1 Suppl) S7-S19
3. Wang, M. H.; Wang, D.; Chen, Y. Q. Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinase Carcinogenesis 2003, 24 (8) 1291-300
4. Benvenuti, S.; Comoglio, P. M. The MET receptor tyrosine kinase in invasion and metastasis J. Cell Physiol. 2007, 213 (2) 316-25
5. Qian, F.; Engst, S.; Yamaguchi, K.; Yu, P.; Won, K. A.; Mock, L.; Lou, T.; Tan, J.; Li, C.; Tam, D.; Lougheed, J.; Yakes, F. M.; Bentzien, F.; Xu, W.; Zaks, T.; Wooster, R.; Greshock, J.; Joly, A. H. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases Cancer Res. 2009, 69 (20) 8009-16
6. Seiwert, T. Y.; Jagadeeswaran, R.; Faoro, L.; Janamanchi, V.; Nallasura, V.; El Dinali, M.; Yala, S.; Kanteti, R.; Cohen, E. E.; Lingen, M. W.; Martin, L.; Krishnaswamy, S.; Klein-Szanto, A.; Christensen, J. G.; Vokes, E. E.; Salgia, R. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma Cancer Res. 2009, 69 (7) 3021-31
7. Catenacci, D. V. T.; Cervantes, G.; Yala, S.; Nelson, E. A.; El-Hashani, E.; Kanteti, R.; El Dinali, M.; Hasina, R.; Bragelmann, J.; Seiwert, T.; Sanicola, M.; Henderson, L.; Grushko, T. A.; Olopade, O.; Karrison, T.; Bang, Y. J.; Kim, W. H.; Tretiakova, M.; Vokes, E.; Frank, D. A.; Kindler, H. L.; Huet, H.; Salgia, R. RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma Cancer Biol. Ther. 2011, 12 (1) 9-46
8. Hsu, P. Y.; Liu, H. S.; Cheng, H. L.; Tzai, T. S.; Guo, H. R.; Ho, C. L.; Chow, N. H. Collaboration of RON and epidermal growth factor receptor in human bladder carcinogenesis J. Urol. 2006, 176 (5) 2262-2267
9. Lee, W. Y.; Chen, H. H. W.; Chow, N. H.; Su, W. C.; Lin, P. W.; Guo, H. R. Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients Clin. Cancer Res. 2005, 11 (6) 2222-2228
10. Cheng, H. L.; Liu, H. S.; Lin, Y. J.; Chen, H. H. W.; Hsu, P. Y.; Chang, T. Y.; Ho, C. L.; Tzai, T. S.; Chow, N. H. Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder Br. J. Cancer 2005, 92 (10) 1906-1914
11. Chen, Q.; Seol, D. W.; Carr, B.; Zarnegar, R. Co-expression and regulation of Met and Ron proto-oncogenes in human hepatocellular carcinoma tissues and cell lines Hepatology 1997, 26 (1) 59-66
12. Maggiora, P.; Lorenzato, A.; Fracchioli, S.; Costa, B.; Castagnaro, M.; Arisio, R.; Katsaros, D.; Massobrio, M.; Comoglio, P. M.; Flavia Di Renzo, M. The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness Exp. Cell Res. 2003, 288 (2) 382-9
13. Koh, Y. W.; Hwang, H. S.; Jung, S. J.; Park, C.; Yoon, D. H.; Suh, C.; Huh, J. Receptor tyrosine kinases MET and RON as prognostic factors in diffuse large B-cell lymphoma patients receiving R-CHOP Cancer Sci. 2013, 104 (9) 1245-1251
14. Lee, C. T.; Chow, N. H.; Su, P. F.; Lin, S. C.; Lin, P. C.; Lee, J. C. The prognostic significance of RON and MET receptor coexpression in patients with colorectal cancer Dis. Colon Rectum 2008, 51 (8) 1268-1274
15. Comperat, E.; Roupret, M.; Chartier-Kastler, E.; Bitker, M. O.; Richard, F.; Camparo, P.; Capron, F.; Cussenot, O. Prognostic value of MET, RON and histoprognostic factors for urothelial carcinoma in the upper urinary tract J. Urol. 2008, 179 (3) 868-872
16. Follenzi, A.; Bakovic, S.; Gual, P.; Stella, M. C.; Longati, P.; Comoglio, P. M. Cross-talk between the proto-oncogenes Met and Ron Oncogene 2000, 19 (27) 3041-9
17. McCleese, J. K.; Bear, M. D.; Kulp, S. K.; Mazcko, C.; Khanna, C.; London, C. A. Met interacts with EGFR and Ron in canine osteosarcoma Vet. Comp. Oncol. 2013, 11 (2) 124-139
18. Oh, Y. M.; Song, Y. J.; Lee, S. B.; Jeong, Y.; Kim, B.; Kim, G. W.; Kim, K. E.; Lee, J. M.; Cho, M. Y.; Choi, J.; Nam, D. H.; Song, P. H.; Cheong, K. H.; Kim, K. A. A new anti-c-Met antibody selected by a mechanism-based dual-screening method: therapeutic potential in cancer Mol. Cells 2012, 34 (6) 523-9
19. Schoffski, P.; Garcia, J. A.; Stadler, W. M.; Gil, T.; Jonasch, E.; Tagawa, S. T.; Smitt, M.; Yang, X.; Oliner, K. S.; Anderson, A.; Zhu, M.; Kabbinavar, F. A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma BJU Int. 2011, 108 (5) 679-86
20. Tabernero, J.; Elez, M. E.; Herranz, M.; Rico, I.; Prudkin, L.; Andreu, J.; Mateos, J.; Carreras, M. J.; Han, M.; Gifford, J.; Credi, M.; Yin, W.; Agarwal, S.; Komarnitsky, P.; Baselga, J. A pharmacodynamic/pharmacokinetic study of ficlatuzumab in patients with advanced solid tumors and liver metastases Clin. Cancer Res. 2014, 20 (10) 2793-804
21. Parr, C.; Jiang, W. G. Expression of hepatocyte growth factor/scatter factor, its activator, inhibitors and the c-Met receptor in human cancer cells Int. J. Oncol. 2001, 19 (4) 857-863
22. Miyazawa, K.; Shimomura, T.; Kitamura, A.; Kondo, J.; Morimoto, Y.; Kitamura, N. Molecular cloning and sequence-analysis of the cDNA for a human tissue serine protease responsible for activation of hepatocyte growth-factor- Structural similarity of the protease precursor to blood coagulation factor-XII J. Biol. Chem. 1993, 268 (14) 10024-10028
23. Shimomura, T.; Kondo, J.; Ochiai, M.; Naka, D.; Miyazawa, K.; Morimoto, Y.; Kitamura, N. Activation of the zymogen of hepatocyte growth-factor activator by thrombin J. Biol. Chem. 1993, 268 (30) 22927-22932
24. Mukai, S.; Fukushima, T.; Naka, D.; Tanaka, H.; Osada, Y.; Kataoka, H. Activation of hepatocyte growth factor activator zymogen (pro-HGFA) by human kallikrein 1-related peptidases FEBS J. 2008, 275 (5) 1003-1017
25. Miyazawa, K.; Shimomura, T.; Kitamura, N. Activation of hepatocyte growth factor in the injured tissues is mediated by hepatocyte growth factor activator J. Biol. Chem. 1996, 271 (7) 3615-3618
26. Shimomura, T.; Miyazawa, K.; Komiyama, Y.; Hiraoka, H.; Naka, D.; Morimoto, Y.; Kitamura, N. Activation of hepatocyte growth factor by two homologous proteases, blood-coagulation factor XIIa and hepatocyte growth factor activator Eur. J. Biochem. 1995, 229 (1) 257-61
27. Owen, K. A.; Qiu, D.; Alves, J.; Schumacher, A. M.; Kilpatrick, L. M.; Li, J.; Harris, J. L.; Ellis, V. Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA Biochem. J. 2010, 426 (2) 219-28
28. Ganesan, R.; Kolumam, G. A.; Lin, S. J.; Xie, M. H.; Santell, L.; Wu, T. D.; Lazarus, R. A.; Chaudhuri, A.; Kirchhofer, D. Proteolytic activation of pro-macrophage-stimulating protein by hepsin Mol. Cancer Res. 2011, 9 (9) 1175-86
29. List, K. Matriptase: a culprit in cancer? Future Oncol. 2009, 5 (1) 97-104
30. Bugge, T. H.; Antalis, T. M.; Wu, Q. Y. Type II Transmembrane Serine Proteases J. Biol. Chem. 2009, 284 (35) 23177-23181
31. Kataoka, H.; Miyata, S.; Uchinokura, S.; Itoh, H. Roles of hepatocyte growth factor (HGF) activator and HGF activator inhibitor in the pericellular activation of HGF/scatter factor Cancer Metastasis Rev. 2003, 22 (2-3) 223-236
32. Parr, C.; Sanders, A. J.; Jiang, W. G. Hepatocyte growth factor activation inhibitors: therapeutic potential in cancer Anticancer Agents Med. Chem. 2010, 10 (1) 47-57
33. Steinmetzer, T.; Schweinitz, A.; Sturzebecher, A.; Donnecke, D.; Uhland, K.; Schuster, O.; Steinmetzer, P.; Muller, F.; Friedrich, R.; Than, M. E.; Bode, W.; Sturzebecher, J. Secondary amides of sulfonylated 3-amidinophenylalanine. New potent and selective inhibitors of matriptase J. Med. Chem. 2006, 49 (14) 4116-26
34. Chevillet, J. R.; Park, G. J.; Bedalov, A.; Simon, J. A.; Vasioukhin, V. I. Identification and characterization of small-molecule inhibitors of hepsin Mol. Cancer Ther. 2008, 7 (10) 3343-3351
35. Ganesan, R.; Eigenbrot, C.; Wu, Y.; Liang, W. C.; Shia, S.; Lipari, M. T.; Kirchhofer, D. Unraveling the allosteric mechanism of serine protease inhibition by an antibody Structure 2009, 17 (12) 1614-1624
36. Lin, J.; Deng, H.; Jin, L.; Pandey, P.; Quinn, J.; Cantin, S.; Rynkiewicz, M. J.; Gorga, J. C.; Bibbins, F.; Celatka, C. A.; Nagafuji, P.; Bannister, T. D.; Meyers, H. V.; Babine, R. E.; Hayward, N. J.; Weaver, D.; Benjamin, H.; Stassen, F.; Abdel-Meguid, S. S.; Strickler, J. E. Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants J. Med. Chem. 2006, 49 (26) 7781-91
37. Shimomura, T.; Ochiai, M.; Kondo, J.; Morimoto, Y. A novel protease obtained from FBS-containing culture supernatant, that processes single chain form hepatocyte growth factor to two chain form in serum-free culture Cytotechnology 1992, 8 (3) 219-29
38. Colombo, E.; Desilets, A.; Duchene, D.; Chagnon, F.; Najmanovich, R.; Leduc, R.; Marsault, E. Design and synthesis of potent, selective inhibitors of matriptase ACS Med. Chem. Lett. 2012, 3 (7) 530-4
39. Deng, H.; Bannister, T. D.; Jin, L.; Babine, R. E.; Quinn, J.; Nagafuji, P.; Celatka, C. A.; Lin, J.; Lazarova, T. I.; Rynkiewicz, M. J.; Bibbins, F.; Pandey, P.; Gorga, J.; Meyers, H. V.; Abdel-Meguid, S. S.; Strickler, J. E. Synthesis, SAR exploration, and X-ray crystal structures of factor XIa inhibitors containing an alpha-ketothiazole arginine Bioorg. Med. Chem. Lett. 2006, 16 (11) 3049-54
40. Shia, S.; Stamos, J.; Kirchhofer, D.; Fan, B.; Wu, J.; Corpuz, R. T.; Santell, L.; Lazarus, R. A.; Eigenbrot, C. Conformational lability in serine protease active sites: Structures of hepatocyte growth factor activator (HGFA) alone and with the inhibitory domain from HGFA inhibitor-1B J. Mol. Biol. 2005, 346 (5) 1335-1349
41. Bhatt, A. S.; Welm, A.; Farady, C. J.; Vasquez, M.; Wilson, K.; Craik, C. S. Coordinate expression and functional profiling identify an extracellular proteolytic signaling pathway Proc. Natl. Acad. Sci. U.S.A. 2007, 104 (14) 5771-6
42. Herter, S.; Piper, D. E.; Aaron, W.; Gabriele, T.; Cutler, G.; Cao, P.; Bhatt, A. S.; Choe, Y.; Craik, C. S.; Walker, N.; Meininger, D.; Hoey, T.; Austin, R. J. Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers Biochem. J. 2005, 390 (Pt 1) 125-36